Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AACBR vs OKYO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OKYO Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 7–1 Matrix Metrics)

OKYO Overall Winner 6-Pillar Tally: AACBR 1 – 2 OKYO (3 Tie) Matrix Metrics: AACBR 1 – 7 OKYO

As of Nov 20, 2026, OKYO Pharma Limited (OKYO) is the stronger overall head-to-head candidate over AACBR (AACBR) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). AACBR carries a Unified Composite Score of 48.2/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas OKYO carries 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AACBR currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. OKYO 42.8/100 HOLD), OKYO captures the overall institutional head-to-head verdict (7–1 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: AACBR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AACBR vs OKYO
AACBR US Equity
AACBR
Institutional Equity
$0.01
+81.82% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -3.40β · 4548% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
OKYO NASDAQ Head-to-Head Winner
OKYO Pharma Limited Ordinary Shares
Biological Products, (No Diagnostic Substances)
$1.07
-7.76% 1D
Market Cap $62.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 76% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 50.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 32
RSI-14: 31.8 · SMA20: $1.35 · SMA50: $1.38

6-Pillar Scorecard Institutional Category Breakdown (AACBR 1 – 2 OKYO)

Columns: Metric · AACBR · OKYO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale OKYO
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $62.7M
3. Profitability & Quality OKYO
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -263.8%
4. Balance Sheet & Cash Flow AACBR
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $0.23 Book/Sh · -263.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AACBR (1) vs OKYO (7)
Institutional Metric AACBR OKYO Criterion Row Edge
Market Capitalization
Scale
N/A $62.7M Larger Scale OKYO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth OKYO
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin OKYO
Net Profit Margin
Profitability
N/A 0.0% Higher Margin OKYO
Return on Equity (ROE)
Capital Efficiency
N/A -263.8% Higher ROE OKYO
52-Week Range Position
Momentum
1% ($0–$1) 3% ($1–$3) Stronger Trend OKYO
Beta / 30D Volatility
Risk Regime
-3.40β · 4548% Vol 1.05β · 76% Vol Lower Realized Risk OKYO
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 42.8 / 100 (HOLD) Higher Composite AACBR
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A ($0.23 Book/Sh · -263.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OKYO +87.63 pp
AACBR: -96.67% · OKYO: -9.04%
3M Horizon OKYO +92.52 pp
AACBR: -98.15% · OKYO: -5.63%
6M Horizon OKYO +77.16 pp
AACBR: -98.1% · OKYO: -20.94%
1Y Horizon OKYO +77.16 pp
AACBR: -98.1% · OKYO: -20.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AACBR vs OKYO. Trailing 12-month operating profitability (AACBR N/A vs OKYO 0.0%) and valuation multiples (AACBR N/M vs OKYO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AACBR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
OKYO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-263.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AACBR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AACBR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OKYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OKYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AACBR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OKYO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AACBR vs OKYO Key Questions & Quantitative Answers

As of Nov 20, 2026, OKYO Pharma Limited (OKYO) is the stronger overall head-to-head candidate over AACBR (AACBR) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). AACBR carries a Unified Composite Score of 48.2/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas OKYO carries 42.8/100 (HOLD) at $1.07 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AACBR currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. OKYO 42.8/100 HOLD), OKYO captures the overall institutional head-to-head verdict (7–1 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: AACBR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile OKYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OKYO leads the Growth & Scale pillar: AACBR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with OKYO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AACBR generates N/A in USD-normalized revenue versus N/A for OKYO. In operating R&D and SG&A reinvestment, AACBR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OKYO.

AACBR and OKYO trade at balanced relative valuation multiples. AACBR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas OKYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AACBR (N/A ROE) versus OKYO (-263.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AACBR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-3.40β · 4548% Vol realized risk). By comparison, OKYO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.